Enanta Pharma Appoints New CMO and Head of Research

TL;DR

Enanta Pharma beefs up leadership with new CMO & Head of Research to push pipeline forward.

AI Summary

Enanta Pharmaceuticals, Inc. announced on March 6, 2024, the appointment of Dr. Jay L. D. Weinstein as Chief Medical Officer and Dr. Sarah J. De Bruin as Senior Vice President, Head of Research. These appointments are part of the company's ongoing efforts to advance its pipeline of novel therapeutics.

Why It Matters

The appointment of experienced leaders in medical and research roles signals Enanta's commitment to progressing its drug development programs, potentially impacting future clinical trial success and product innovation.

Risk Assessment

Risk Level: low — The filing primarily concerns executive appointments, which are routine and do not immediately indicate significant financial or operational risks.

Key Players & Entities

• Enanta Pharmaceuticals, Inc. (company) — Registrant
• Dr. Jay L. D. Weinstein (person) — Appointed Chief Medical Officer
• Dr. Sarah J. De Bruin (person) — Appointed Senior Vice President, Head of Research
• March 06, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select

Filing Documents

• enta-20240306.htm (8-K) — 70KB
• enta-ex10_1.htm (EX-10.1) — 137KB
• 0000950170-24-029889.txt ( ) — 342KB
• enta-20240306.xsd (EX-101.SCH) — 24KB
• enta-20240306_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. At the Annual Meeting held on March 6, 2024, Enanta's stockholders voted on the following proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 26, 2024. Proposal No. 1: To Elect Three Class II Directors to Serve until the 2027 Annual Meeting or until their respective successors are elected and qualified. The stockholders re-elected the following individuals as Class II directors of the Company: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Yujiro S. Hata 13,127,063 2,392,002 1,156,191 Kristine Peterson 12,994,324 2,524,741 1,156,191 Terry C. Vance 12,169,732 3,209,519 1,296,005 Proposal No. 2: To Approve an Amendment to Our 2019 Equity Incentive Plan. The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 975,000 shares. Votes For Votes Against Abstain Broker Non-Votes 8,076,566 7,421,300 21,356 1,156,034 Proposal No. 3: To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers. The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote. Votes For Votes Against Abstain Broker Non-Votes 12,306,697 3,196,342 16,183 1,156,034 Proposal No. 4: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2024 Fiscal Year. The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2024. Votes For Votes Against Abstain Broker Non-Votes 14,571,800 27,373 2,076,083 0

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 10.1 104 2019 Equity Incentive Plan (As amended March 2024) Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENANTA PHARMACEUTICALS, INC. Date: March 12, 2024 By: /s/ Paul J. Mellett Paul J. Mellett Chief Financial and Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR